Please assess the completion status of the following clinical trial:

Trial Title: Multi-centre Study to Compare Efficacy and Safety of AFOLIA and Gonal-f in Women for Assisted Reproductive Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 20 and 38 years with regular menstrual cycles of 25-35 days~* First or second cycle in the present series of ART~* BMI ≥ 18 ≤ 30 kg/m2~* Basal FSH \< 10 IU/L (cycle day 2-5)~* E2 levels \< 50pg/mL (\< 0.18 nmol/L) at the day of FSH administration~* Antral follicle count (AFC) ≥ 10 to ≤ 25 follicles (sum of both ovaries)~* Infertility due to any of the following factors: tubal factor, mild endometriosis (ASRM stage 1-2), male factor, unexplained infertility~* Presence of both ovaries and normal uterine cavity (confirmed by transvaginal ultrasound within 6 months before randomisation)~* Willingness to participate in the study and to comply with the study protocol~* Informed consent~Exclusion Criteria:~* Presence of pregnancy~* History of ≥2 succeeding ART cycles (IVF and/or ICSI) before the study cycle without clinical pregnancy~* Presence of clinically significant systemic disease~* Presence of chronic cardiovascular, hepatic, renal or pulmonary disease~* Presence of uncontrolled endocrine disorder~* Previous history or presence of severe ovarian hyperstimulation syndrome~* Presence of polycystic ovaries (PCO)~* Presence of severe endometriosis (ASRM stage 3 or stage 4) and hydrosalpinx~* Neoplasia, including tumors of the hypothalamus and pituitary gland~* Abnormal bleeding of undetermined origin~* History of poor response to gonadotropin treatment (defined as fewer than 5 oocytes retrieved in a previous attempt)~* Male infertility without mobile spermatozoa in the ejaculate, that need testicular of epididymal sperm retrieval (MESA/TESE/TESA)~* Endocrine abnormality such as TSH or prolactin level elevations outside the reference range if clinically relevant at screening~* Any hormonal treatment within 1 month before the start of the FSH treatment (with the exception of levothyroxin)~* History of drug, nicotine or alcohol abuse within the last 12 months (\> 10 cigarettes/day)~* Administration of other investigational products within the last month~* Clinically abnormal findings at Visit 1~* Planned PGS/PGD/PBB or assisted hatching~* Concomitant participation in an other study protocol~* History of extrauterine pregnancy in the previous 3 months~* Known allergy or hypersensitivity to progesterone or to any of the excipients (including peanut oil) of the additional study medication (GnRH agonist, vitrelle®, and Utrogestan®)~* Presence or history of thrombophlebitis or thromboembolic disorders~* Presence or history of cerebral haemorrhage~* Presence or history of porphyria

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- Gonal-f® (Follitropin alfa) (Type: ACTIVE_COMPARATOR): None
- AFOLIA-150 (Follitropin alfa) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).